Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway

Background: Ovarian cancer is the most lethal female genital malignancy. Although cisplatin is the first-line chemotherapy to treat ovarian cancer patients along with debulking surgeries, its efficacy is limited due to the high incidence of cisplatin resistance. ATP citrate lyase (ACLY) has been sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Xuan, Shi, Juanjuan, Lin, Qianhan, Ma, Xiaoxue, Pang, Yingxin, Mao, Hongluan, Li, Rui, Lu, Wei, Wang, Yu, Liu, Peishu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011496/
https://www.ncbi.nlm.nih.gov/pubmed/33816292
http://dx.doi.org/10.3389/fonc.2021.642229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011496/
https://www.ncbi.nlm.nih.gov/pubmed/33816292
http://dx.doi.org/10.3389/fonc.2021.642229

Ejemplares similares